2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B |
Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
Gross Profit | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B |
Gross Profit % | 100% | 100% | 100% | 100% | 100% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $370M | $547M | $704M | $666M | $688M |
Dep. & Amort. | $0 | $3.3M | -$749K | $0 | $0 |
Def. Tax | $11M | -$1.4M | -$2.3M | -$1.8M | $4.5M |
Stock Comp. | $0 | $1.5M | $9.9M | $15M | $19M |
Chg. in WC | $310M | $21M | -$158M | -$62M | -$53M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $453M | $426M | $514M | $616M | $599M |
ST Investments | $5B | $5.3B | $4.9B | $5.3B | $5.6B |
Cash & ST Inv. | $5.5B | $5.7B | $5.4B | $616M | $6.2B |
Receivables | $46M | $42M | $42M | $45M | $53M |
Inventory | -$686M | -$739M | -$777M | $0 | $0 |
Enact reported strong Q1 2025 results, with adjusted operating income of $169M (up 2% YoY), adjusted EPS of $1.10 (up 6% YoY), and adjusted ROE of 13.4%; insurance in force grew 2% YoY to $258B.
The company announced a new $350M share repurchase authorization and a 14% dividend increase to $0.21 per share, reaffirming 2025 total capital return guidance of $350M, similar to 2024 levels.
Credit performance remained robust: total delinquencies decreased 5% sequentially, new delinquencies dropped 11%, and the cure rate was strong at 56%, resulting in a $47M reserve release and a loss ratio of 12%.
Operating expenses improved, down 9% sequentially and 1% YoY; 2025 expense guidance is reaffirmed at $220M–$225M (excluding reorganization costs).
Management highlighted a resilient, seasoned portfolio with an average age of 3.9 years, stable pricing, and prudent underwriting; the company is well-positioned for macroeconomic uncertainty with a PMIERs sufficiency ratio of 165% and continued focus on risk-adjusted returns.